Therapeutic opportunities of the IL-22-IL-22R1 system - PubMed (original) (raw)

Review

doi: 10.1038/nrd4176.

Affiliations

Review

Therapeutic opportunities of the IL-22-IL-22R1 system

Robert Sabat et al. Nat Rev Drug Discov. 2014 Jan.

Abstract

Interleukin-22 (IL-22) is a key effector molecule that is produced by activated T cells, including T helper 22 (TH22) cells, TH17 cells and TH1 cells, as well as subsets of innate lymphoid cells. Although IL-22 can act synergistically with IL-17 or tumour necrosis factor, some important functions of IL-22 are unique to this cytokine. Data obtained over the past few years indicate that the IL-22-IL-22 receptor subunit 1 (IL-22R1) system has a high potential clinical relevance in psoriasis, ulcerative colitis, graft-versus-host disease, certain infections and tumours, as well as in liver and pancreas damage. This Review highlights current knowledge of the biology of the IL-22-IL-22R1 system, its role in inflammation, tissue protection, regeneration and antimicrobial defence, as well as the positive and potentially negative consequences of its therapeutic modulation.

PubMed Disclaimer

References

    1. FEBS Lett. 2008 Sep 3;582(20):2985-92 - PubMed
    1. Mucosal Immunol. 2013 Jan;6(1):69-82 - PubMed
    1. J Clin Invest. 2008 Feb;118(2):597-607 - PubMed
    1. Mol Cell Biochem. 2012 Oct;369(1-2):255-66 - PubMed
    1. N Engl J Med. 2012 Jan 12;366(2):158-64 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources